1. Home
  2. NAMS vs ENLT Comparison

NAMS vs ENLT Comparison

Compare NAMS & ENLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • ENLT
  • Stock Information
  • Founded
  • NAMS 2019
  • ENLT 2008
  • Country
  • NAMS Netherlands
  • ENLT Israel
  • Employees
  • NAMS N/A
  • ENLT N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • ENLT
  • Sector
  • NAMS Health Care
  • ENLT
  • Exchange
  • NAMS Nasdaq
  • ENLT Nasdaq
  • Market Cap
  • NAMS 2.3B
  • ENLT 1.9B
  • IPO Year
  • NAMS N/A
  • ENLT 2023
  • Fundamental
  • Price
  • NAMS $20.12
  • ENLT $16.01
  • Analyst Decision
  • NAMS Strong Buy
  • ENLT Buy
  • Analyst Count
  • NAMS 6
  • ENLT 4
  • Target Price
  • NAMS $33.80
  • ENLT $19.00
  • AVG Volume (30 Days)
  • NAMS 634.7K
  • ENLT 11.0K
  • Earning Date
  • NAMS 11-06-2024
  • ENLT 11-13-2024
  • Dividend Yield
  • NAMS N/A
  • ENLT N/A
  • EPS Growth
  • NAMS N/A
  • ENLT N/A
  • EPS
  • NAMS N/A
  • ENLT 0.41
  • Revenue
  • NAMS $33,594,000.00
  • ENLT $358,416,000.00
  • Revenue This Year
  • NAMS N/A
  • ENLT $428.35
  • Revenue Next Year
  • NAMS N/A
  • ENLT $27.54
  • P/E Ratio
  • NAMS N/A
  • ENLT $38.82
  • Revenue Growth
  • NAMS 78.77
  • ENLT 47.65
  • 52 Week Low
  • NAMS $8.90
  • ENLT $14.09
  • 52 Week High
  • NAMS $26.35
  • ENLT $20.00
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 44.60
  • ENLT 50.90
  • Support Level
  • NAMS $19.59
  • ENLT $14.96
  • Resistance Level
  • NAMS $25.32
  • ENLT $16.48
  • Average True Range (ATR)
  • NAMS 1.44
  • ENLT 0.50
  • MACD
  • NAMS -0.32
  • ENLT 0.06
  • Stochastic Oscillator
  • NAMS 36.35
  • ENLT 71.13

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About ENLT Enlight Renewable Energy Ltd.

Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. It operates across the three largest renewable segments namely solar, wind and energy storage. Geographically, it operates in the United States, Israel and 9 European countries.

Share on Social Networks: